Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

HilleVax, Inc. - Common Stock (NQ: HLVX )

1.860 +0.030 (+1.64%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about HilleVax, Inc. - Common Stock

HilleVax Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress
From HilleVax, Inc.
Via GlobeNewswire
HilleVax Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress
From HilleVax, Inc.
Via GlobeNewswire
HilleVax Announces Reduction in Force
From HilleVax, Inc.
Via GlobeNewswire
HilleVax, Inc. (HLVX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
HilleVax, Inc. (HLVX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
HLVX Investors Have Opportunity to Join HilleVax, Inc. Securities Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
HilleVax Reports Topline Data from NEST-IN1 Phase 2b Clinical Study of HIL-214 in Infants
From HilleVax, Inc.
Via GlobeNewswire
HilleVax Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
From HilleVax, Inc.
Via GlobeNewswire
HilleVax Reports Full Year 2023 Financial Results and Highlights Recent Company Progress
From HilleVax, Inc.
Via GlobeNewswire
HilleVax to Present at Guggenheim 6th Annual Biotechnology Conference
From HilleVax, Inc.
Via GlobeNewswire
HilleVax Announces Executive Management Appointment of Sean McLoughlin as Chief Operating Officer
From HilleVax, Inc.
Via GlobeNewswire
HilleVax and Kangh Announce Exclusive License Agreement for Hexavalent VLP Norovirus Vaccine Candidate Outside of China
Collaboration leverages HilleVax’s leading norovirus vaccine development expertise and adds a Phase 1-ready next-generation program to HilleVax’s pipeline 
From HilleVax, Inc.
Via GlobeNewswire
HilleVax to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From HilleVax, Inc.
Via GlobeNewswire
HilleVax Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
From HilleVax, Inc.
Via GlobeNewswire
HilleVax to Present at Upcoming Investor Conferences
From HilleVax, Inc.
Via GlobeNewswire
HilleVax to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference
From HilleVax, Inc.
Via GlobeNewswire
HilleVax Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From HilleVax, Inc.
Via GlobeNewswire
HilleVax Announces Pricing of Public Offering of Common Stock
From HilleVax, Inc.
Via GlobeNewswire
HilleVax Announces Proposed Public Offering of Common Stock
From HilleVax, Inc.
Via GlobeNewswire
HilleVax Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
From HilleVax, Inc.
Via GlobeNewswire
HilleVax Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
From HilleVax, Inc.
Via GlobeNewswire
HilleVax Announces Appointment of Nanette Cocero Ph.D., MBA, to its Board of Directors
From HilleVax, Inc.
Via GlobeNewswire
HilleVax Announces Completion of Enrollment of NEST-IN1 Phase 2b Clinical Study of HIL-214 Norovirus Vaccine Candidate
From HilleVax, Inc.
Via GlobeNewswire
HilleVax Reports Full Year 2022 Financial Results and Highlights Recent Company Progress
From HilleVax, Inc.
Via GlobeNewswire
HilleVax Announces Executive Management Appointments and Promotions
From HilleVax, Inc.
Via GlobeNewswire
HilleVax to Present at the 41st Annual J.P. Morgan Healthcare Conference
From HilleVax, Inc.
Via GlobeNewswire
HilleVax Announces Positive Immunogenicity Results for Run-In Cohort of NEST-IN1 Phase 2b Clinical Trial of HIL-214 Norovirus Vaccine Candidate
From HilleVax, Inc.
Via GlobeNewswire
HilleVax to Participate in November Investor Conferences
From HilleVax, Inc.
Via GlobeNewswire
HilleVax Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
From HilleVax, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.